Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
Diabetes Drafting Group. Prevalence of small vessellarge vessel disease in diabetic patients from 14 centers theWorld HealthOrganization multinational Study of Vascular Disease in Diabetics.
Diabetologia, 28 (1985), pp. 615-640
[2.]
J. Stamler, O. Vaccaro, J.D. Neaton, D. Wentworth.
Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial.
Diabetes Care, 6 (1993), pp. 434-444
[4.]
P. Henry, S. Makowski, P. Richard, F. Beverelli, S. Casanova, A. Louali, et al.
Increased incidence of moderate stenosis among patients with diabetes: substrate for myocardial infarction?.
Am Heart J, 134 (1997), pp. 1037-1043
[5.]
R.J. Jarrett, M.J. Shipley.
Type 2 (non-insulin dependent) diabetes mellitus and cardiovascular disease: putative association via common antecedents; further evidence from the Whitehall Study.
Diabetologia, 31 (1988), pp. 737-740
[6.]
S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, M. Laakso.
Mortality from coronary heart disease in subjects with Type 2 diabetesand in nondiabetic subjects with and without prior myocardial infarction.
N Engl J Med, 339 (1998), pp. 229-234
[7.]
K. Malmberg, S. Yusuf, H.C. Gerstein, J. Brown, F. Zhao, D. Hunt, et al.
Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry.
Circulation, 102 (2000), pp. 1014-1049
[8.]
Third Report of the National Cholesterol Education Program (NCEP)Expert Panel on DetectionEvaluation,Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) finalreport.
Circulation, 106 (2002), pp. 3143-3421
[9.]
AmericanDiabetes Association. Clinical practice recommendation.
Diabetes Care, 26 (2003), pp. S1-156
[10.]
R. Carmena.
Dislipemia diabética.
Hiperlipemias. Clínica y tratamiento, pp. 139-153
[11.]
P.W.F. Wilson, W.B. Kannel, K.M. Anderson.
Lipids, glucose intolerance and vascular disease: the Framingham study.
Monographs on atherosclerosis, pp. 1-11
[12.]
K. Pyörälä, T.R. Pedersen, J. Kjekshus, O. Faergeman, A.G. Olsson, G. Thorgeirsson.
Cholesterol lowering with simvastatin improvesprognosis of diabetic patients with coronary heart disease.
Diabetes Care, 20 (1997), pp. 614-620
[13.]
F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutheford, T.G. Cole.
The cholesterol and recurrent events trial investigation: the effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
N Engl J Med, 335 (1996), pp. 1001-1009
[14.]
The Long Term Intervention with Pravastatin in Ischaemic Heart Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart diasease and a broad range of initial cholesterol levels.
N Engl J Med, 339 (1998), pp. 1349-1357
[15.]
M. Laakso.
Benefits of strict glucose and blood pressure control in type 2 diabetes: lessons from the UK Prospective Diabetes Study.
Circulation, 99 (1999), pp. 461-462
[16.]
S.F. Dinneen, H.C. Gerstein.
The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systemic overview of the literature.
Arch Intern Med, 157 (1997), pp. 1413-1418
[17.]
B. Dahlöf, R.D. Devereux, S.E. Kjeldsen, S. Julius, G. Beevers, U. De Faire, LIFE Study Group.
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lancet, 359 (2002), pp. 995-1003
[18.]
T.J. Lyons, A.J. Jemkins.
Lipoprotein glycation and its metabolic consequences.
Curr Opin Lipidol, 8 (1997), pp. 174-180
[19.]
J. Kuusisto, L. Mykkanen, K. Pyorala, M. Laakso.
Niddm and its metabolic control predict coronary heart disease in elderly subjects.
Diabetes, 43 (1994), pp. 960-967
[20.]
M. SerranoRíos, J.F. Ascaso, E. Blázquez-Fernández, J. CabezasCerrato, R. Carmena, F. Escobar, et al.
La resistencia a la insulina y su implicación en múltiples factores de riesgo asociados a diabetes tipo 2.
Med Clin (Barc, 119 (2002), pp. 458-463
[21.]
Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.
Bmj, 308 (1994), pp. 81-106
[22.]
M. Pfohl, H. Schatz.
Strategies for the prevention of type 2 diabetes.
Exp Clin Endocrinol Diabetes, 109 (2001), pp. S240-249
[23.]
X.R. Pan, G.W. Li, Y.H. Hu, J.X. Wang, W.Y. Yang, Z.X. An, et al.
Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study.
Diabetes Care, 20 (1997), pp. 537-544
[24.]
H. Borghouts, A. Keizer.
Exercise and insulin sensitivity: a review.
Int J Sports Med, 21 (2000), pp. 1-12
[25.]
W.C. Knowler, E. Barret-Connor, S.E. Fowler, R.F. Hamman, J.M. Lachin, E.A. Walker, et al.
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
N Engl J Med, 346 (2002), pp. 393-403
[26.]
J. Tuomilehto, J. Lindstrom, J.G. Eriksson, T.T. Valle, H. Hamalainen, P. Ilanne-Parikka, et al.
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.
N Engl J Med, 344 (2001), pp. 1343-1350
[27.]
S.H. Saydah, C.M. Loria, M.S. Eberhardt, F.L. Brancati.
Subclinical states of glucose intolerance and risk of death in the US.
Diabetes Care, 24 (2001), pp. 447-453
[28.]
B. Isomaa, P. Almgren, T. Tuomi, B. Forsen, K. Lahti, M. Nissen, et al.
Cardiovascular morbidity and mortality associated with the metabolic syndrome.
Diabetes Care, 24 (2001), pp. 683-689
La relación de autores que pertenecen al Grupo de Trabajo Diabetes Mellitus y Enfermedad Cardiovascular de la Sociedad Española de Diabetes aparece al final del artículo.
Copyright © 2004. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.